News

Symrise invests in innovative enzymatic technology with sugar alternative experts Bonumose

Symrise AG has signed a minority investment agreement with Bonumose. The early-stage food ingredient manufacturer specializes in the affordable production of delicious, good-for-you rare monosaccharides (alternatives to sucrose) such as tagatose and allulose. With this strategic transaction, Symrise will accelerate growth in its sugar reduction initiatives. The area represents a high-priority focus for the North America region within the Taste, Nutrition & Health segment.

“This exciting investment forges a strategic partnership. It will enhance our flavor and taste balancing technologies with Bonumose’s innovative and economical tagatose and other alternative sweetening solutions. Combining our technologies, will enable us to offer our customers new pathways to sugar reduction and taste balancing solutions. In turn, this will allow them to reduce sugar while optimizing the taste of better-for-you products for their consumers. This applies especially in the beverage and ice-cream categories. Health forms a growing focus category for Symrise. With the support of Bonumose’s enzymatic expertise, we can bring novel and disrupting ingredients to the marketplace together”, said Nick Russell, Senior Vice President – Business Incubation Group, Symrise AG.

Bonumose opened a new R&D facility and manufacturing plant earlier this year. The facility allows for quality, consistent, and economic production of their growing portfolio of sugar alternatives. Bonumose was founded in 2016 as a start-up. It continues to grow thanks to their patented enzymatic technology. This allows for the sustainable bulk production of healthy ingredients from globally-abundant plant material.

Ed Rogers, Bonumose Chief Executive Officer and Co-Founder, said: “We feel enthusiastic about the future and the growth that the investment and partnership with Symrise enables. Now, we are coupling our expertise in tagatose and other naturally-occurring sugar alternatives with the extensive Symrise flavor proficiency and expansive portfolio across multiple platforms in both human food and animal nutrition. This creates the opportunity to offer unique value to customers. The strength of Symrise as an augmented flavor house paired with Bonumose’s patented enzymatic technology will enable cutting edge solutions to sugar reduction.”

Recent News

06/29/2026

Stemora receives NSF SBIR Phase I award to advance breakthrough cartilage regeneration technology

Stemora Inc., a Maryland-based biotechnology company developing next-generation regenerative therapies for osteoarthritis and cartilage injuries, today announced that it has been awarded a $305,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant. The award supports Stemora’s development of a one-step, intraoperative regenerative therapy designed to restore durable hyaline cartilage by activating

06/29/2026

Stemora receives NSF SBIR Phase I award to advance breakthrough cartilage regeneration technology

Stemora Inc., a Maryland-based biotechnology company developing next-generation regenerative therapies for osteoarthritis and cartilage injuries, today announced that it has been awarded a $305,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant. The award supports Stemora’s development of a one-step, intraoperative regenerative therapy designed to restore durable hyaline cartilage by activating

06/23/2026

Scout Space raises Series A second close from VTC Ventures, Long Knife, and 100KM

Scout Space, a space domain awareness sensor and software provider, has announced the second close of its Series A financing, adding VTC Ventures, Long Knife and 100KM to its investor syndicate. The initial close occurred in May 2026, led by Washington Harbour Partners. The funding will accelerate deployment of Scout’s in-orbit sensor network, support upcoming